Protection from Hendra virus infection with Canarypox recombinant vaccine
Authors:
Open Access
- 28 July 2016
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 1 (1) , 16003
Abstract
Hendra virus (HeV) is an emerging zoonotic pathogen, which causes severe respiratory illness and encephalitis in humans and horses. Since its first appearance in 1994, spillovers of HeV from its natural reservoir fruit bats occur on almost an annual basis. The high mortality rate in both humans and horses and the wide-ranging reservoir distribution are making HeV a serious public health problem, especially for people exposed to sick horses. This study has aimed to develop an efficient low-cost HeV vaccine for horses based on Canarypox recombinant vector expressing HeV glycoproteins, attachment glycoprotein (G) and fusion protein (F). This vaccine was used to immunise hamsters and then challenged intraperitoneally with HeV 3 weeks later. The higher tested dose of the vaccine efficiently prevented oropharyngeal virus shedding and protected animals from clinical disease and virus-induced mortality. Vaccine induced generation of seroneutralising antibodies and prevented virus-induced histopathological changes and a production of viral RNA and antigens in animal tissues. Interestingly, some vaccinated animals, including those immunised at a lower dose, were protected in the absence of detectable specific antibodies, suggesting the induction of an efficient virus-specific cellular immunity. Finally, ponies immunised using the same vaccination protocol as hamsters developed strong seroneutralising titres against both HeV and closely related Nipah virus, indicating that this vaccine may have the ability to induce cross-protection against Henipavirus infection. These data suggest that Canarypox-based vectors encoding for HeV glycoproteins present very promising new vaccine candidate to prevent infection and shedding of the highly lethal HeV.Keywords
This publication has 40 references indexed in Scilit:
- Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 monthsVirology Journal, 2013
- Henipavirus Infections: Lessons from Animal ModelsPathogens, 2013
- A Hendra Virus G Glycoprotein Subunit Vaccine Protects African Green Monkeys from Nipah Virus ChallengeScience Translational Medicine, 2012
- Unexpected Result of Hendra Virus Outbreaks for Veterinarians, Queensland, AustraliaEmerging Infectious Diseases, 2012
- A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus ChallengeScience Translational Medicine, 2011
- A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challengeVaccine, 2011
- Person-to-Person Transmission of Nipah Virus in a Bangladeshi CommunityEmerging Infectious Diseases, 2007
- Feline Model of Acute Nipah Virus Infection and Protection with a Soluble Glycoprotein-Based Subunit VaccineJournal of Virology, 2006
- Recombinant Nipah Virus Vaccines Protect Pigs against ChallengeJournal of Virology, 2006
- Antibody and IFN-γ responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virusVeterinary Immunology and Immunopathology, 2006